Please sign in to follow a disease.
New care bundle aims to keep transplant patients on track with lifesaving meds
NCT ID NCT07447388
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study will develop and test a care bundle—a set of best practices—to help heart transplant patients stick to their immunosuppressive (anti-rejection) medication. The bundle will be created with input from patients and healthcare providers, then tested in 100 patients over 6 months. The goal is to standardize care and improve medication adherence, which is critical to prevent organ rejection.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- immunosuppressive medication adherence care bundle (a set of evidence-based practices to improve medication adherence)
- What this could lead to
- If successful, this care bundle could become a standard tool to help transplant patients take their medications correctly, potentially reducing organ rejection and improving long-term health.
- What could go wrong
- This is a small, early-stage study (100 patients) testing a behavioral intervention, not a drug. It may not show a clear benefit, and results may not apply to all transplant patients or settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
May 2026
An estimate. Start dates often move.
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Being 18 years of age or older * Having no communication barriers * Being literate * Being able to speak and understand Turkish * Having no diagnosed psychiatric disorder * Meeting the discharge criteria from the clinic after organ transplantation Exclusion Criteria: * Being followed up in the intensive care unit due to complications or other reasons * Unwillingness to continue participating in the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Transplant patients are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.